Drug intelligence / Profile preview

Nustem

Development stage: Unknown
Lead developer: Daehan Nupharm
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

Nustem (DHNP-D01) is a veterinary cell therapy product developed by Daehan Nupharm, currently in Phase 3 clinical trials for the treatment of canine disc herniation and spinal cord injury. The therapy consists of adipose-derived mesenchymal stem cells (AD-MSCs), which are utilized for their regenerative, anti-inflammatory, and immunomodulatory properties. By secreting various growth factors and cytokines, Nustem aims to repair damaged neural tissues and alleviate the symptoms of intervertebral disc disease (IVDD) in dogs, potentially offering a therapeutic alternative to surgery. The product is designed as an off-the-shelf regenerative treatment to improve neurological function and quality of life in pets suffering from debilitating spinal conditions.

Brand names: Nustem

Beyond the preview

Go deeper on Nustem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nustem.

Explore the full profile